#	Pagina
attuale pagina	/open-h2020/projects/199760/index.html

Opendata, web and dolomites

H2020MM04 SIGNED

DC-based immunotherapy to treat Malignant Mesothelioma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Outcomes and
results

H2020MM04 project word cloud

Explore the words cloud of the H2020MM04 project. It provides you a very rough idea of what is the project "H2020MM04" about.

designation adverse treat health actions 2065 limited immunotherapy extensive treatments clinical disease environment millions rotterdam events ema cisplatin survival aggressive scientific tumour occupational combination orphan carcinogens cell signs therapy resolution 06 market 1229 autologous mm consumers ini date quantities twice last fda fibres pemetrexed time lysate malignant threats mesothelioma exposed dendritic iarc banned first trial immuno despite fatal standard months 2012 treatment massively median history workers protecting pulmonary tremendously consisting 12 registration poor curative personalised risk allogeneic extremely chemotherapy union 13 16 24 therapeutic asbestos incidence inhalation international diseases illness abolishing 2014 2010 cells january prolonged netherlands resistant death erasmus deaths considerably granted reported care approval mc prospects pulsed

Project "H2020MM04" data sheet

The following table provides information about the project.

Coordinator	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM Organization address address: DR MOLEWATERPLEIN 40 city: ROTTERDAM postcode: 3015 GD website: www.erasmusmc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	https://www.denimstudy.eu/
Total cost	5˙782˙965 €
EC max contribution	5˙782˙965 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-PHC-2015-two-stage
Funding Scheme	RIA
Starting year	2016
Duration (year-month-day)	from 2016-01-01 to 2021-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM Organization address address: DR MOLEWATERPLEIN 40 city: ROTTERDAM postcode: 3015 GD website: www.erasmusmc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (ROTTERDAM)	coordinator	2˙375˙146.00
2	UNIVERSITA POLITECNICA DELLE MARCHE UNIVERSITA POLITECNICA DELLE MARCHE Organization address address: PIAZZA ROMA 22 city: ANCONA postcode: 60121 website: www.univpm.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ANCONA)	participant	669˙452.00
3	STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS Organization address address: PLESMANLAAN 121 city: AMSTERDAM postcode: 1066 CX website: www.nki.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	participant	669˙451.00
4	UNIVERSITY OF LEICESTER UNIVERSITY OF LEICESTER Organization address address: UNIVERSITY ROAD city: LEICESTER postcode: LE1 7RH website: www.le.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LEICESTER)	participant	669˙215.00
5	UNIVERSITAIR ZIEKENHUIS ANTWERPEN UNIVERSITAIR ZIEKENHUIS ANTWERPEN Organization address address: WILRIJKSTRAAT 10 city: EDEGEM postcode: 2650 website: www.uza.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (EDEGEM)	participant	668˙874.00
6	CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE Organization address address: AVENUE OSCAR LAMBRET 2 city: LILLE postcode: 59037 website: http://www.chru-lille.fr/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (LILLE)	participant	659˙822.00
7	AMPHERA BV AMPHERA BV Organization address address: ONDERWIJSBOULEVARD 225 city: DEN BOSCH postcode: 5223 DE website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (DEN BOSCH)	participant	48˙000.00
8	EUROPEAN CANCER PATIENT COALITION EUROPEAN CANCER PATIENT COALITION Organization address address: RUE MONTOYER 40 city: BRUXELLES postcode: 1000 website: www.ecpc-online.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BRUXELLES)	participant	23˙000.00

Map

Project objective

Asbestos is one of the major occupational carcinogens. The European Union has an extensive history of protecting workers and consumers against asbestos and even adopted a resolution 2012/2065(INI) ‘on asbestos related occupational health threats and prospects for abolishing all existing asbestos’ last year. Although asbestos is banned, it is still massively present in the built environment. Millions of workers & consumers in the EU were, and still are, for many years exposed to asbestos fibres, despite all measures.

Inhalation of even very low quantities of asbestos fibres tremendously increases the risk of developing Malignant Mesothelioma (MM). The IARC reported 8.100 MM deaths in 2010 in the EU. Despite all EU actions, MM incidence is still increasing. MM is a highly fatal disease with a poor median survival time from first signs of illness to death around 12 months despite aggressive treatments. To date there is no curative therapy for MM. MM is considered as an extremely therapy-resistant disease. Chemotherapy consisting of a combination of pemetrexed and cisplatin is considered standard of care with a median survival increase of 3 months (9-12 months).

The department of pulmonary diseases of the Erasmus MC, Rotterdam, The Netherlands, in collaboration with international partners, have developed a promising personalised immunotherapy for MM with very limited adverse effects. The first clinical results show a considerably prolonged average survival with limited adverse events (24 months, twice as long).

The EMA and the FDA granted this therapy Orphan Designation: autologous dendritic cells pulsed with allogeneic tumour cell lysate for the treatment of malignant mesothelioma (EU: 16 January 2014 - EU/3/13/1229; FDA – US: 06 May 2014).

The objective for the project is to deliver the scientific & registration package for market approval by the EMA of a novel immuno therapeutic approach to treat MM. This includes the execution of a phase II/III clinical trial.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "H2020MM04" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "H2020MM04" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More

SBR (2020)

SMART BONE REGENERATION

Read More